

Obstructive sleep apnoea: Potential role of tumour necrosis factor alpha as a circulating biomarker

Ambreen Qamar¹, Zeba Haque², Sitwat Zehra³, Mirza Saifullah Baig⁴

Abstract

Objective: To assess the relationship of tumour necrosis factor-alpha with obstructive sleep apnoea and its severity in Pakistani population.

Method: The cross-sectional study was conducted at the Sleep Laboratory of Dow University Hospital, Karachi, from December, 2018, to March, 2020, and comprised patients of either gender having symptoms of snoring, witnessed apnoea or daytime sleepiness. They were divided into four groups on the basis of obstructive sleep apnoea status. Those without obstructive sleep apnoea were in Group A, mild status in Group B, moderate in Group C and severe obstructive sleep apnoea in Group D. Polysomnography was done to confirm obstructive sleep apnoea status and to categorise the subjects using apnoea-hypopnoea index, while enzyme-linked immunosorbent assay was used to assess their tumour necrosis factor alpha levels. Data was analysed using SPSS 20.

Results: Of the 150 subjects, 94(63%) were males. The overall mean age was 49.68±12.14 years. There were 50(33.33%) subjects in Group A, 19(12.66%) Group B, 23(15.33%) Group C and 58(38.66%) in Group D. Mean tumour necrosis factor-alpha level was 3.88±1.65pg/mL in Group A, 9.97±4.33 pg/mL in Group B, 12.65±4.46 pg/mL in Group C and 12.83±4.33 pg/mL in Group D. Mean tumour necrosis factor-alpha levels had significant association with the severity of obstructive sleep apnoea ($p<0.001$).

Conclusion: Higher levels of tumour necrosis factor-alpha were found to be associated with obstructive sleep apnoea, and can be considered a potential biomarker for early diagnosis.

Keywords: Sleep, Obstructive sleep apnoea, Biomarker, TNF-alpha, Inflammation, Sleep-related breathing disorder.

(JPMA 72: 1350; 2022) DOI: <https://doi.org/10.47391/JPMA.3239>

Introduction

Obstructive sleep apnoea (OSA) is a common sleep disorder which causes problems ranging from declining quality of life (QOL) to end-organ morbidities and deaths. It is associated with disturbed metabolic profile, diabetes, cardiovascular complications like atrial fibrillation (A-fib), hypertension (HTN), coronary artery disease (CAD), congestive heart failure (CHF), excessive sleepiness, decreased functional capacity and mental alertness, decreased productivity, impaired learning and memory, as well as with motor vehicle and occupational accidents.^{1,2} It is characterised by recurring episodes of complete (apnoea) or partial (hypopnoea) upper airway collapse during sleep, lasting >10 seconds, with ≥5 obstructive episodes per hour of sleep with oxygen haemoglobin desaturation ≥3%. It is accompanied by excessive daytime sleepiness (EDS), intermittent hypoxaemia (IH), hypercapnia, frequent arousal from sleep, fragmented

sleep architecture, higher respiratory efforts, intra-thoracic negative pressure swings and increased sympathetic system activity which are considered the reason for a great number of physiological derangements in these subjects.³⁻⁵ The severity of OSA is measured by the frequency of apnoea and hypopnoea per hour of sleep, called the apnoea hypopnoea index (AHI), recorded using polysomnography (PSG) which is the gold standard diagnostic test for OSA that works to record electrophysiological signals during sleep.⁶ EDS, which is a cardinal feature of OSA, can be determined by Epworth sleepiness scale (ESS), which is a validated brief questionnaire. It determines the likelihood of falling asleep during different daily life situations. Score >9 indicate EDS and, as such, the chance of having OSA.⁷ OSA is the cause of a considerable burden on individual and public health and is evaluated to affect 34% of males and 17% of females.⁸

Tumour necrosis factor-alpha (TNF-α) is an important multifunctional proinflammatory cytokine mostly secreted by mononuclear macrophages, Natural Killer (NK) cells and other immune cells.⁹ Its role in a variety of physiological function and various disease aetiologies has been studied and is well-documented. TNF-α influences whole organism functions, such as body temperature, inflammation,

¹Department of Physiology, Dr. Ishrat-ul-Ebad Khan Institute of Oral Health Sciences, Dow University of Health Sciences, Karachi, Pakistan; ²Department of Biochemistry, Dow University of Health Sciences, Karachi, Pakistan;

³Dr. A.Q Khan Institute of Biotechnology, and Engineering, University of Karachi, Karachi, Pakistan; ⁴Department of Drug Resistant T.B, Dow University of Health Sciences, Karachi, Pakistan.

Correspondence: Ambreen Qamar. e-mail: ambreenqamar243@gmail.com

appetite, neurogenesis, cognition, memory, depression, micro-circulation, fatigue/performance.¹⁰ It plays a crucial role in host defence and its inappropriate production is the origin to several diseases, such as cancer, infectious disease and cardiovascular diseases (CVDs) like atherosclerosis.⁹ One important implication of its role is in sleep regulation. Substantial evidence indicates that acute enhancement of TNF- α promote sleep while its inhibition inhibits sleep. It has been shown to promote non-rapid eye movement sleep (NREMS) duration in every species tested.^{3,10} Studies have demonstrated the up-regulation of TNF- α expression in animal models of sleep disturbance along with cognitive and mood disturbances, while reversal of these disturbances were seen after treatment with TNF- α neutralising antibody.³

A number of studies have been conducted in Pakistan to examine TNF- α association with some diseases, like diabetes,¹¹ congenital heart diseases,¹² osteoporosis,¹³ metabolic syndrome¹⁴ and in relation to X-ray exposure.¹⁵ No study has evaluated the role of TNF- α in OSA, which is a neglected but potentially harmful condition. The current study was planned to fill the gap by assessing the relationship of TNF- α with OSA and its severity.

Subjects and Methods

The cross-sectional study was conducted at the Sleep Laboratory of Dow University Hospital, Karachi, from December, 2018, to March, 2020. After approval from the ethics review committee of the Dow University of Health Sciences (DUHS), Karachi, the sample size was calculated using OpenEpi online calculator,¹⁶ using mean difference from an earlier research.² The sample was raised using consecutive sampling technique. An informed consent in English/Urdu was explained and got signed from all individual(s) before participation. Those included were patients of either gender having symptoms of snoring, witnessed apnoea or daytime sleepiness, having indication for polysomnography with ESS score >9. The cases were selected after confirmation of OSA through overnight polysomnography (Alice 6 LDX, Philips Respironics) under continuous monitoring. Those with current surgery, pregnancy or individuals with current serious illness were excluded.

The subjects were divided into four groups on the basis of their OSA status; those without OSA Group A, mild OSA Group B, moderate OSA Group C, and severe OSA Group D. Polysomnographic assessment demonstrated characteristics of sleep phases as well as AHI. OSA subjects were categorised as mild (AHI: 5-15), moderate (AHI: 15-30) and severe (AHI>30) based on the Chicago Criteria by the American

Academy of Sleep Medicine.¹⁷ History and demographic information were compiled using a predesigned proforma. Vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) was used to collect 5ml venous blood sample, after PSG recording between 6am and 8 am. Samples were processed on centrifuge machine for 20min with 2000rpm and the separated plasma was stored at -80°C until further investigations.

Plasma TNF- α levels were measured using commercial enzyme-linked immunosorbent assay (ELISA) kits (DIA source, S.A. Belgium). Manufacturer's protocol was strictly monitored and followed for sample handling, temperature control, procedures and for other steps. Bichromatic readings were calculated by using the mean of duplicate determinations.

Data was analysed using SPSS 20. Quantitative variables were expressed as mean+standard deviation, while qualitative variables were described as frequencies and percentages. Mean TNF- α values were compared among the four OSA-based groups using analysis of variance (ANOVA). Analysis of covariance (ANCOVA) was used to assess mean TNF- α value in relation to OSA severity after controlling the potential effect of age and body mass index (BMI). $P<0.05$ was considered statistically significant.

Results

Of the 150 subjects, 94(63%) were males. The overall mean age was 49.68 \pm 12.14 years. It was 45.92 \pm 11.82 years in Group A, 49.67 \pm 12.15 years in Group B, 54.83 \pm 14.72 years in Group C, and 50.53 \pm 10.33 years in group D. There were 50(33.33%) subjects in Group A, 19(12.66%) Group B, 23(15.33%) Group C and 58(38.66%) in Group D. Mean AHI for apnoea subjects was 25.21 \pm 24.92, while mean ESS scores for all groups was 10.57 \pm 6.03. Mean TNF- α level was 3.88 \pm 1.65pg/mL in Group A, 9.97 \pm 4.33pg/mL in Group B, 12.65 \pm 4.46pg/mL in Group C and 12.83 \pm 4.33pg/mL in Group D. There was no significant difference for TNF- α values with respect to gender ($p=0.180$). Mean TNF- α levels had significant association with OSA severity ($p<0.001$) (Table 1).

Table-1: Comparison of TNF- α levels, Age, ESS scores, AHI scores and BMI in different groups of obstructive sleep apnoea.

Severity of OSA	TNF α levels	Age	ESS Score	AHI Score	BMI
	Mean \pm SD	Mean \pm SD	Mean \pm SD	Mean \pm SD	Mean \pm SD
No OSA (n=50)	3.88 (1.56)	45.92 (11.82)	4.10 (2.02)	0.01 (0.04)	26.53 (5.65)
Mild OSA (n=19)	9.97 (4.33)	49.67 (12.15)	9.11 (3.46)	8.40 (4.36)	31.02 (4.93)
Moderate OSA (n=23)	12.65 (4.46)	54.83 (14.72)	12.30 (2.94)	24.77 (5.79)	34.01 (6.71)
Severe OSA (n=58)	12.83 (4.33)	50.53 (10.33)	15.91 (4.10)	52.32 (14.15)	37.29 (6.88)
<i>p</i> -value	<0.001	0.023	<0.001	<0.001	<0.001

TNF- α : Tumour necrosis factor alpha, ESS: Epworth sleepiness scale, AHI: Apnoea-hypopnoea index, BMI: Body mass index, OSA: Obstructive sleep apnoea.

Table-2: Mean differences of TNF-α in different groups of obstructive sleep apnoea.

Severity of OSA	Severity of OSA	Mean Difference	p-value	95% Confidence Interval	
				Lower Bound	Upper Bound
No OSA	Mild OSA	-6.0897	<0.001	-8.670	-3.509
	Moderate OSA	-8.7743	<0.001	-11.187	-6.362
	Severe OSA	-8.9499	<0.001	-10.798	-7.102
Mild OSA	No OSA	6.0897	<0.001	3.509	8.670
	Moderate OSA	-2.6846	0.092	-5.653	0.284
	Severe OSA	-2.8602	0.020	-5.391	-0.329
Moderate OSA	No OSA	8.7743	<0.001	6.362	11.187
	Mild OSA	2.6846	0.092	-0.284	5.653
	Severe OSA	-0.1756	0.997	-2.535	2.184
Severe OSA	No OSA	8.9499	<0.001	7.102	10.798
	Mild OSA	2.8602	0.020	0.329	5.391
	Moderate OSA	0.1756	0.997	-2.184	2.535

TNF-α: Tumour necrosis factor alpha, OSA: Obstructive sleep apnoea.

Table-3: Association between TNF-α levels and severity of OSA-after controlling for age and BMI in ANCOVA model.

Source	F (D.F)	p-value	Partial Eta Squared (%)
Severity of OSA	34.20 (3)	<0.001	41.60%
Age	0.43 (1)	0.512	0.30%
BMI	2.12 (1)	0.147	1.50%

TNF α: Tumour necrosis factor alpha, BMI: Body mass index, OSA: Obstructive sleep apnoea, DF: Degree of freedom, ANCOVA: Analysis of covariance.




Figure: Adjusted Tumour necrosis factor alpha (TNF-α) levels according to different groups of obstructive sleep apnoea (OSA).

There was significant difference among all groups except between Groups B and C (p=0.092) and between Groups C and D (p=0.997) (Table 2).

Mean TNF-α levels showed significant association with OSA severity as explained by partial eta squared value of the total variance remaining after accounting for variance explained by other variables, like age and BMI in the model (Table 3, Figure).

Discussion

The findings suggest that TNF-α could be considered a biomarker for OSA patients with different levels of severity. Previous studies from different countries have reported conflicting data. Some have observed significantly higher levels of circulating TNF-α in OSA, while others did not.¹⁸ More interestingly, there is a wide difference in plasma levels in different populations, like a Chinese study showed higher levels of TNF-α plasma levels in both OSA and controls,¹⁹ while lower levels in both OSA and controls were reported in American population.²⁰ Both studies, however, showed significantly higher levels in OSA compared to controls. A Japanese study reported 1.11 pg/ml and 0.60pg/ml levels in severe OSA and controls respectively²⁰ and another

study reported 28.60 pg/ml 25.00 pg/ml levels in severe OSA and controls.¹⁸ In the current study it ranged from 12.83 to 3.88 pg/ml in severe OSA to no OSA group. This wide differences in TNF-α levels indicate that it is not only due to ethnicity, but also the study population and difference in methodology. Yoshikawa et al. examined 22 OSA patients and found a positive correlation of TNF-α with AHI.²¹ Ming et al. examined 684 OSA subjects and 192 healthy controls, and found significantly higher TNF-α levels in cases (31.2±5.3 vs 12.1±1.1).² The current study found a positive association of TNF levels with AHI, and the finding was in line with earlier studies,¹⁷⁻²⁰ which demonstrated the association of TNF-α with sleep-related breathing disorders and suggested that TNF suppression could decrease OSA progression. Studies have suggested that airway inflammation might have a role in the pathogenesis and natural history of OSA. ¹

On the other hand, some studies have reported contradictory results. Behboudi et al. examined Swedish OSA population and didn't get positive results for this association.⁵ Dogan et al. evaluated a sample of Turkish population, with 33 OSA and 24 control subjects, and didn't find significant difference between them (p=0.722).⁴ Two main differences between the earlier studies (4,5) and the current study were in terms of sample size and ESS scores. With a larger sample size, the current study is more convinced for its findings. Secondly, the presence of EDS, indicated by high ESS score, even in their control groups could be a factor to get similar results in both groups. They explained that higher ESS scores in the controls could be due to age, circadian factors and medical problems, while the current study selected its controls after evaluating their ESS scores.

These diverse findings reflect the fact that TNF-α levels can be influenced by a number of factors, such as CVDs, HTN,

diabetes, asthma, smoking, certain medications as well as the heterogeneity of the selected population.¹⁴

Multiple mechanisms can be considered to understand this relationship. Freitas et al. explained its role to promote NREMS and the targeted disruption or inhibition of its receptors for the suppression of NREMS.²² Kheirandish et al. demonstrated that TNF- α leads to the stimulation of nuclear factor kappa B (NF- κ B) pathways which leads to the activation of nitric oxide synthase, cyclooxygenase 2 and adenosine A1 receptors, and all of them are associated with sleep regulation. In an animal sleep fragmentation model similar to OSA, a study revealed nervous and other body tissues with considerable up-regulation of TNF- α expression, as well as cognitive and mood problems, comparable to those appearing in OSA.²³ Furthermore, marked reduction of all symptoms were noticed after treatment with TNF- α neutralising antibody, including sleep and behavioural disturbances.^{3,23}

Although many OSA patients develop end-organ morbidities, but not all, which reflects the variability of clinical phenotype requiring proper investigation, particularly in relation to the inflammation. Continuous positive airway pressure (CPAP) therapy is a prime treatment option for OSA patients¹⁸ but it is not well-tolerated by many patients. Better understanding of pathophysiology is crucial to find more treatment options, especially for those who are not able to tolerate CPAP therapy.

It is believed that TNF- α could be a reason to promote upper airway dysfunction and other mechanism that lead to onset of OSA, but one should not neglect the possibility of reciprocal relationships, that OSA encourages a pro-inflammatory state and leads to higher TNF- α levels.³ Some studies described sleep deprivation and hypoxaemia as the causative factors for higher TNF- α levels in OSA.⁴ Halloran et al. described that intermittent hypoxaemia (IH), which is an essential feature of OSA, can encourage carotid body inflammation and leads to altered immune regulation and disruption in control of breathing that may predispose respiratory instability during sleep.²⁴

Cardiovascular complications that frequently accompany OSA are thought to develop as a result of inflammatory stress associated with cytokines, such as TNF- α . Previous studies have been described TNF- α as a predictor of future cardiovascular incidents and mortality.⁴ Many intermediate mechanisms have been proposed for the relationship of TNF- α , OSA and cardio-metabolic complications. Higher TNF- α may causes procoagulant activity and the deposition of fibrin, resulting in higher production of peroxide and cardiovascular damages. TNF- α may also cause

neovascularisation and formation of atherosclerosis in OSA patients. Furthermore, TNF- α causes increased expression of adhesion molecules, causes lymphocytes activation and severe inflammatory reactions in lesion area.² It is, therefore, suggested that higher TNF- α levels could be the potential link between OSA and its cardio-metabolic comorbidities.

Biomarkers can provide insight into the pathological mechanisms of the disease and propose new therapeutic strategies. Based on the findings, the current study suggests that TNF- α has an important role in OSA pathophysiology, and could be a link between OSA and its co-morbidities via inflammatory pathways. However, exploration of systemic inflammatory pathways is not conclusive in finding a particular biomarker as a prognostic factor for OSA or causative agent for related co-morbidities. Furthermore, given the frequency of co-morbidities in OSA, which, by themselves, increase the cardiovascular risk, all confounders are considerable factors. Future large-scale studies are suggested with interventional models comprising pre- and post-treatment assessment, and careful scrutiny of multiple potential confounders that are possibly related to OSA.³

Since data was collected from a single centre, the findings of the current study need to be generalised carefully.

Conclusion

A significant association was found between OSA and TNF- α , which may be involved in the occurrence and progression of OSA and might be a promising biomarker for OSA diagnosis. It can also be used to assess OSA severity and may facilitate the implementation of better treatment strategies for OSA patients in Pakistan. This relationship might also explain the higher incidence of CVDs and metabolic disorders in these patients.

Disclaimer: None.

Conflict of interest: None.

Source of Funding: None.

References

1. Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. *J Clin Sleep Med* 2019; 15: 301-4.
2. Ming H, Tian A, Liu B, Hu Y, Liu C, Chen R, et al. Inflammatory cytokines tumor necrosis factor-alpha, interleukin-8 and sleep monitoring in patients with obstructive sleep apnea syndrome. *Exp Ther Med* 2019; 17: 1766-70.
3. Kheirandish-Gozal L, Gozal D. Obstructive Sleep Apnea and Inflammation: Proof of Concept Based on Two Illustrative Cytokines. *Int J Mol Sci* 2019; 20: 459.

4. Ünüvar Doğan F, Yosunkaya S, Kuzu Okur K, Can U. Relationships between Obstructive Sleep Apnea Syndrome, Continuous Positive Airway Pressure Treatment, and Inflammatory Cytokines. *Sleep Disord* 2014; 2014: 518920.
5. Behboudi A, Thelander T, Yazici D, Celik Y, Yucel-Lindberg T, Thunstrom E, et al. Association of TNF-alpha (-308G/A) Gene Polymorphism with Circulating TNF-alpha Levels and Excessive Day time Sleepiness in Adults with Coronary Artery Disease and Concomitant Obstructive Sleep Apnea. *J Clin Med* 2021; 10: 3413.
6. Mullins AE, Kam K, Parekh A, Bubu OM, Osorio RS, Varga AW. Obstructive Sleep Apnea and Its Treatment in Aging: Effects on Alzheimer's disease Biomarkers, Cognition, Brain Structure and Neurophysiology. *Neurobiol Dis* 2020; 145: 105054.
7. Guo Q, Song WD, Li W, Zeng C, Li YH, Mo JM, et al. Weighted Epworth sleepiness scale predicted the apnea-hypopnea index better. *Respir Res* 2020; 21: 147.
8. Tietjens JR, Claman D, Kezirian EJ, De Marco T, Mirzayan A, Sadroonri B, et al. Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy. *J Am Heart Assoc* 2019; 8: e010440.
9. Cao Y, Song Y, Ning P, Zhang L, Wu S, Quan J, et al. Association between tumor necrosis factor alpha and obstructive sleep apnea in adults: a meta-analysis update. *BMC Pulm Med* 2020; 20: 215.
10. Rockstrom MD, Chen L, Taishi P, Nguyen JT, Gibbons CM, Veasey SC, et al. Tumor necrosis factor alpha in sleep regulation. *Sleep Med Rev* 2018; 40: 69-78.
11. Ijaz F, Aftab RK, Zubair SM, Aftab RR. Correlation of Tumor Necrosis Factor alpha with obesity induced insulin resistance in type 2 Diabetes Mellitus. *Pak J Physiol* 2018; 14: 18-20.
12. Shahramian I, Noori NM, Hashemi M, Sharafi E, Baghbanian A. A study of serum levels of leptin, ghrelin and tumour necrosis factor-alpha in child patients with cyanotic and acyanotic, congenital heart disease. *J Pak Med Assoc* 2013; 63: 1332-7.
13. Murad R, Shezad Z, Ahmed S, Ashraf M, Qadir M, Rehman R. Serum tumour necrosis factor alpha in osteopenic and osteoporotic postmenopausal females: A cross-sectional study in Pakistan. *J Pak Med Assoc* 2018; 68: 428-31.
14. Zafar U, Khaliq S, Ahmad HU, Lone KP. Serum profile of cytokines and their genetic variants in metabolic syndrome and healthy subjects: a comparative study. *Biosci Rep* 2019; 39: BSR20181202.
15. Rehman K, Mustafa G, Ayub H, Ullah I, Alam MR, Khan MA. Expression analysis of tumour necrosis factor alpha (TNF-alpha) and alkaline phosphatase in occupational workers exposed to low dose of X-radiation: A case-control study. *J Pak Med Assoc* 2020; 70: 1887-96.
16. Sullivan KM, Dean A, Soe MM. OpenEpi: a web-based epidemiologic and statistical calculator for public health. *Public Health Rep* 2009; 124: 471-4.
17. McNicholas WT. Diagnostic criteria for obstructive sleep apnea: time for reappraisal. *J Thorac Dis* 2018; 10: 531-3.
18. Li Q, Zheng X. Tumor necrosis factor alpha is a promising circulating biomarker for the development of obstructive sleep apnea syndrome: a meta-analysis. *Oncotarget* 2017; 8: 27616-26.
19. Liu H, Liu J, Xiong S, Shen G, Zhang Z, Xu Y. The change of interleukin-6 and tumor necrosis factor in patients with obstructive sleep apnea syndrome. *J Tongji Med Univ* 2000; 20: 200-2.
20. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. *J Clin Endocrinol Metab* 1997; 82: 1313-6.
21. Yoshikawa M, Yamauchi M, Fujita Y, Koyama N, Fukuoka A, Tamaki S, et al. The impact of obstructive sleep apnea and nasal CPAP on circulating adiponectin levels. *Lung* 2014; 192: 289-95.
22. de Araujo Freitas IG, de Bruin PF, Bittencourt L, de Bruin VM, Tufik S. What can blood biomarkers tell us about cardiovascular risk in obstructive sleep apnea? *Sleep Breath* 2015; 19: 755-68.
23. Ramesh V, Nair D, Zhang SX, Hakim F, Kaushal N, Kayali F, et al. Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-alpha pathway. *J Neuroinflammation* 2012; 9: 91.
24. O'Halloran KD, Lewis P, McDonald F. Sex, stress and sleep apnoea: Decreased susceptibility to upper airway muscle dysfunction following intermittent hypoxia in females. *Respir Physiol Neurobiol* 2017; 245: 76-82.